First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

This is a first-in-human study testing a new drug called GSK5471713 in men with advanced prostate cancer that has spread (metastatic) and is no longer responding to hormone therapy (castration-resistant prostate cancer, or mCRPC). The study is testing the drug's safety and how it works in the body. **You may be eligible if...** - You have been diagnosed with metastatic castration-resistant prostate cancer (confirmed by biopsy) - Your cancer has continued to grow despite hormone therapy - You have received at least one prior hormone-blocking drug and one to two prior chemotherapy regimens - Your overall health and performance level are good (ECOG 0–1) **You may NOT be eligible if...** - Your prostate cancer is a rare subtype (e.g., small cell or neuroendocrine) - You have significant heart problems - You have an uncontrolled infection or serious abnormal lab values - You have previously received a drug that degrades the androgen receptor Talk to your doctor to see if this trial is right for you.